Pages pUse SHIFT+ENTER to open the menu (new window).

This system library was created by the Publishing feature to store pages that are created in this site.

Immunoassay screen for the following drug classes or method groups: barbiturates, cannabinoids, cocaine, and ethanol. Test also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.

Results of this test are presumptive. If confirmatory testing is desired, the confirmatory test(s) can be ordered as add-on (u-have) tests, utilizing the original urine collection, within 9 days of the original test.

This test is intended to compliment the test “Targeted Drug Panel, Urine” (TDPU).

​Trisomy 21

Trisomy 18

Trisomy 13

Monosomy X

Triploidy

22q11.2 Deletion

Chromosome abnormalities

Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, Klinefelter Syndrome, Triple X Syndrome, Jacob's Syndrome

​Amphiphysin Ab, CSF, ANNA-1, CSF, ANNA-2, CSF, ANNA-3, CSF, Anti-Hu, Antineuronal Cerebellar Antibodies, CRMP-5-IgG, CSF, Dorsal Root Ganglion Antibody, Hu Antibody, Neuron Restricted Autoantibodies, Neuronal Nuclear Antibody, Neuronal-Anti, Ovarian Cancer-Related Antibodies, Paraneoplastic Autoantibody Western Blot Confirmation, CSF, Paraneoplastic Neurological Autoimmunity, PCA-1, CSF, PCA-2, CSF, PCA-Tr, CSF, Purkinje Cell Cytoplasmic Antibodies, Ri, Anti, Yo-Anti

B19

Erythrovirus B19

Fifth Disease

Human Parvovirus

Slapped Cheek disease

​blood pH, arterial pH

​pH

​Patch

+3/+7
+9/+15
13q- / -13 (13q deletion) or RB1
17p- (17p deletion) or TP53
-13 (monosomy 13)
IGH (14q32) rearrangement
Monoclonal Gammopathy of Unknown Significance (MGUS)
Multiple Myeloma
MYC (8q24.1) rearrangement
Plasma Cell Leukemia
t(4;14) - FGFR3/IGH
t(6;14) - CCND3/IGH
t(11;14) - CCND1/IGH
t(14;16) - IGH/MAF
t(14;20) - IGH/MAFB
+1q or 1q22

TI PLASFSO

PLM, PLM6S, Platelet Mapping ADP, Platelet Mapping AA

​HKH-MA, ActFMA, ADP-MA, %INH-ADP, %AGG-ADP, AA-MA, %INH-AA, %AGG-AA

​Pneumococcal Antibody Panel (23 Serotypes) (401835P)

Pneumococcal Antibody (IgG) 23 Serotype Panel
Strep Antibodies
Strep Pneumo Antibodies
Strep Pneumoniae Antibody
Strep Vaccine
Streptococcus Pneumoniae
Vaccine

JAK2 V617F

JAK2 exon 12

Polycythemia Vera

Myeloproliferative Neoplasm (MPN)

​Both DNA and RNA are extracted. The algorithm starts with a highly sensitive DNA-based JAK2 V617F test by allele specific polymerase chain reaction. If the JAK2 V617F result is negative or very low positive (0.06%-0.6%), JAK2 exon 12-15 Sanger sequencing test will be performed on the stored RNA sample. If a JAK2 V617F mutation (>0.6%) is detected, the algorithm stops and no further testing will be performed.

The Sanger sequencing covers JAK2 exons 12 through the first 90% of exon 15, which spans the region containing essentially all mutations reported in myeloproliferative neoplasms. The following algorithms are available in Special Instructions.

​Acute Intermittent Porphyria (AIP)
Hereditary Coproporphyria (HCP)
PBG (Porphobilinogen)
Variegate Porphyria (VP)

Porphobilinogen Qnt, U (PBGU)

U PBGUSO

Acute Intermittent Porphyria (AIP)
Congenital Erythropoietic Porphyria (CEP)
Coproporphyrin
Hereditary Coproporphyria (HCP)
PBG (Porphobilinogen)
Porphyria Cutanea Tarda (PCT)
Porphyrins, Fractionation, Urine
Uroporphyrin
Variegate Porphyria (VP)

24 PORPHU

​BRAF, Cardiofaciocutaneous (CFC), CBL, Costello Syndrome (CS), HRAS, KRAS, LEOPARD Syndrome (LS), MAP2K1, MAP2K2, Multiple Lentigines, Next Gen Sequencing Test, Noonan Syndrome (NS), NRAS, PTPN11, RAF1, SHOC2, SOS1, FFPE, Postmortem, Sudden cardiac arrest, Sudden cardiac death, Sudden unexplained death, Sudden death

​This test includes next-generation sequencing and supplemental Sanger sequencing to evaluate the BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, SHOC2, and SOS1 genes.

​Prostate Cancer Screen

TI PROLSO

​Prostate Specific Antigen, Total Hybritech

Adenine, Adenosine, Deoxyadenosine, Deoxyguanosine, Deoxyinosine, Guanosine, Hyperuricemias, Hypoxanthine, Inosine, Orotic Acid, Pyrimidine, Succinyladenosine, Thymidine, Uracil, Thymine, Uric Acid, Uridine, Xanthine, S-Sulfocysteine, Adenine phosphoribosyltransferase deficiency, Adenosine deaminase deficiency, Adenosine monophosphate deaminase deficiency, Adenylosuccinate lyase deficiency, AICAr transformylase/imp cyclohydrolase deficiency, Beta-ureidopropionase deficiency, Carbamoyl phosphate synthetase deficiency, Deoxyguanosine kinase deficiency, Dihydropyrimidinase deficiency, Dihydropyrimidine dehydrogenase deficiency, Hyperornithinemia-hyperammonemia-homocitrullinuria, Lesch-Nyhan syndrome, Molybdenum cofactor deficiency, Phosphoribosyl pyrophosphate synthetase deficiency, Primary hyperoxaluria, Purine metabolism disorders, Purine nucleoside phosphorylase deficiency, Pyrimidine metabolism disorders, Secondary hyperuricemia, Sulfite oxidase deficiency, Thymidine phosphorylase deficiency, Uridine monophosphate synthetase deficiency, Xanthine dehydrogenase and xanthine aldehyde oxidase dual deficiency, Xanthine dehydrogenase deficiency, Xanthine dehydrogenase/xanthine aldehyde oxidase/sulfite oxidase combined deficiency

​Uracil, Thymine, Adenine, Hypoxanthine, Xanthine, Orotic, Dihydroorotic Acid, Uric Acid, Deoxythymidine, Deoxyuridine, Thymidine, Uridine, Deoxyadenosine, Deoxyinosine, Deoxyguanosine, Adenosine, Inosine, Guanoasine, 5-Aminoimidazole-4-carboxyamide 1-beta-D-ribofuranoside (AICAR), Succinyladenosine, S-Sulfocysteine, Dihydrouracil, Dihydrothymine, N-carbomoyl-B-alanine, N-carbomoyl-B-aminoisobutyric Acid